Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
Valganciclovir is a potent antiviral prodrug and a Cytomegalovirus (CMV) nucleoside analog DNA polymerase inhibitor, primarily used to treat CMV retinitis in patients with AIDS and to prevent CMV disease in high-risk organ transplant recipients.
Name
Valganciclovir
Raw Name
VALGANCICLOVIR HYDROCHLORIDE
Category
Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
Salt Form
Hydrochloride
Drug Count
8
Variant Count
27
Last Verified
February 17, 2026
RxCUI
863559, 313566, 284587, 863562
UNII
4P3T9QF9NZ, GCU97FKN3R
About Valganciclovir
Valganciclovir is a potent antiviral prodrug and a Cytomegalovirus (CMV) nucleoside analog DNA polymerase inhibitor, primarily used to treat CMV retinitis in patients with AIDS and to prevent CMV disease in high-risk organ transplant recipients.
Detailed information about Valganciclovir
References used for this content
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Valganciclovir.
Valganciclovir (as Valganciclovir Hydrochloride) is a sophisticated antiviral medication and a member of the pharmacological class known as Cytomegalovirus (CMV) nucleoside analog DNA polymerase inhibitors. It is essentially an L-valyl ester prodrug (a precursor substance) of ganciclovir. Upon oral administration, it is rapidly converted into ganciclovir by intestinal and hepatic esterases (enzymes that break down esters). This conversion is critical because ganciclovir itself has very poor oral bioavailability, whereas Valganciclovir allows for therapeutic levels of the active drug to be reached through oral dosing, often comparable to intravenous ganciclovir administration.
Valganciclovir was first approved by the U.S. Food and Drug Administration (FDA) in 2001 under the brand name Valcyte. It represented a major milestone in the management of Cytomegalovirus (CMV), a common herpesvirus that can cause severe, sight-threatening, or even fatal infections in immunocompromised individuals, such as those living with HIV/AIDS or those who have recently undergone solid organ transplantation. According to the FDA-approved labeling, the drug is indicated for the treatment of CMV retinitis (an infection of the retina) and for the prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients who are at high risk (specifically where the donor is CMV-positive and the recipient is CMV-negative).
To understand how Valganciclovir works, one must look at the molecular lifecycle of the Cytomegalovirus. CMV requires the replication of its DNA to spread and cause tissue damage. Valganciclovir, once converted to ganciclovir, acts as a 'decoy' for the building blocks of viral DNA.
The mechanism occurs in three distinct steps of phosphorylation (the addition of a phosphate group). First, inside the CMV-infected cell, a viral protein kinase (an enzyme) called pUL97 converts ganciclovir into ganciclovir monophosphate. This is a crucial 'selective' step because the viral enzyme is much more efficient at this conversion than human enzymes, meaning the drug is primarily activated within infected cells. Subsequently, several cellular kinases (human enzymes) further phosphorylate the monophosphate into ganciclovir diphosphate and finally into the active form: ganciclovir triphosphate.
Once in the triphosphate form, the drug competes with deoxyguanosine triphosphate (a natural DNA building block) for incorporation into the viral DNA strand by the viral DNA polymerase. When ganciclovir triphosphate is incorporated into the DNA chain, it causes 'chain termination' or significantly slows down the elongation of the viral DNA. This effectively halts the replication of the virus, preventing it from spreading to healthy cells and allowing the host's immune system (even if weakened) or existing therapies to manage the infection.
Understanding the pharmacokinetics (how the body handles the drug) of Valganciclovir is essential for clinical efficacy and safety.
Valganciclovir is primarily utilized in two major clinical scenarios involving immunocompromised patients:
Valganciclovir is available in two primary oral formulations to accommodate different patient needs:
> Important: Only your healthcare provider can determine if Valganciclovir is right for your specific condition. This medication requires careful monitoring of blood counts and kidney function throughout the duration of therapy.
The dosage of Valganciclovir is strictly dependent on the condition being treated and the patient's renal function. According to the standard prescribing information:
Valganciclovir is approved for the prevention of CMV disease in pediatric kidney transplant recipients (aged 4 months to 16 years) and heart transplant recipients (aged 1 month to 16 years). The dose is calculated using a specific formula based on the child's Body Surface Area (BSA) and renal function (CrCl), often referred to as the modified Schwartz formula.
If the calculated CrCl exceeds 150 mL/min/1.73 m², a maximum value of 150 is used in the formula. The maximum daily dose for children should not exceed 900 mg. Healthcare providers must recalculate this dose frequently as the child's weight or kidney function changes.
Since Valganciclovir is primarily cleared by the kidneys, dose adjustments are mandatory for patients with a Creatinine Clearance (CrCl) below 60 mL/min. Failure to adjust the dose can lead to severe toxicity, including profound bone marrow suppression.
The safety and efficacy of Valganciclovir have not been specifically studied in patients with hepatic (liver) impairment. However, since the liver is involved in the conversion of Valganciclovir to ganciclovir, clinicians exercise caution, though no specific dose adjustments are currently mandated by the FDA.
Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased renal function in this population.
If a dose is missed, it should be taken as soon as the patient remembers. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Patients should never 'double up' on doses to make up for a missed one, as this increases the risk of bone marrow toxicity.
An overdose of Valganciclovir can be life-threatening. Symptoms of overdose typically mirror the drug's most severe side effects, including:
In the event of an overdose, the patient should be taken to an emergency room immediately. Hemodialysis and hydration may be used to reduce blood levels of ganciclovir.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this can lead to viral resistance or disease progression.
Valganciclovir is a potent medication, and side effects are frequent, particularly in patients who are already immunocompromised. The following are commonly reported:
> Warning: Stop taking Valganciclovir and call your doctor or emergency services immediately if you experience any of the following:
The FDA has issued a 'Black Box Warning' for Valganciclovir due to the following risks:
Report any unusual symptoms to your healthcare provider immediately. Regular blood monitoring is the only way to catch these side effects early.
Valganciclovir is a high-alert medication that requires close clinical supervision. It is not a cure for CMV; it is a treatment to suppress the virus. Patients must understand that the virus may remain dormant in the body and can reactivate if the medication is stopped or if the immune system weakens further.
As noted in the side effects section, Valganciclovir carries the FDA's most serious warning. This includes Hematologic Toxicity (the risk of life-threatening low blood counts), Impairment of Fertility (potential permanent infertility in men and women), Fetal Toxicity (severe birth defects), and Mutagenesis/Carcinogenesis (potential to cause cancer). These warnings are based on extensive animal data and clinical reports of bone marrow suppression in humans.
To ensure safety, patients on Valganciclovir should expect the following monitoring schedule:
Valganciclovir can cause side effects like seizures, dizziness, ataxia (loss of muscle coordination), and confusion. Patients should not drive or operate heavy machinery until they know how the medication affects them and their healthcare provider confirms it is safe to do so.
While there is no direct chemical interaction between alcohol and Valganciclovir, alcohol can cause dehydration and strain the kidneys. Furthermore, both alcohol and Valganciclovir can cause gastrointestinal upset and dizziness. It is generally advised to limit or avoid alcohol consumption while being treated for a serious viral infection like CMV.
Valganciclovir should not be stopped abruptly without consulting a physician. In transplant patients, stopping the drug early can lead to the development of CMV disease. In HIV patients, stopping maintenance therapy can lead to a rapid flare-up of CMV retinitis and permanent vision loss. There is no specific 'withdrawal syndrome,' but the risk of viral rebound is high.
> Important: Discuss all your medical conditions, especially kidney disease or blood disorders, with your healthcare provider before starting Valganciclovir.
For each major interaction, the mechanism usually involves either additive toxicity (two drugs causing the same side effect) or renal competition (two drugs fighting to be excreted by the kidneys). The management strategy usually involves dose reduction, increased monitoring frequency, or choosing an alternative medication.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter drugs.
> Important: Your healthcare provider will evaluate your complete medical history, including any previous drug allergies or blood disorders, before prescribing Valganciclovir.
Valganciclovir is considered highly dangerous during pregnancy. In animal studies, ganciclovir caused cleft palate, small eyes (anophthalmia/microphthalmia), brain swelling (hydrocephalus), and abnormalities of the skeleton and reproductive system.
It is not known whether Valganciclovir or ganciclovir is excreted in human milk. However, because of the potential for serious adverse reactions in nursing infants (including carcinogenicity and bone marrow suppression), the CDC recommends that HIV-infected mothers do not breastfeed to avoid postnatal transmission of HIV. Furthermore, mothers taking Valganciclovir are generally advised to discontinue nursing.
Valganciclovir is approved for the prevention of CMV disease in pediatric kidney and heart transplant recipients. It is NOT approved for the treatment of congenital CMV (CMV present at birth) or for CMV retinitis in children. The dosing must be meticulously calculated using the BSA/CrCl formula. Long-term safety data regarding growth and development in children are limited, but the risks of bone marrow suppression and potential future infertility remain significant concerns.
Elderly patients are more likely to have age-related decreases in renal function. Since Valganciclovir is renally excreted, the risk of toxic reactions is higher in this group. Clinicians must calculate the Creatinine Clearance (CrCl) rather than just looking at the serum creatinine level, as muscle mass (and thus creatinine production) decreases with age. Dose adjustments are frequently necessary.
Renal impairment is the most critical factor in Valganciclovir dosing. For patients with a CrCl < 60 mL/min, the dosing interval must be extended or the dose reduced (see Usage Instructions). In patients with severe renal failure, the drug can accumulate rapidly, leading to fatal bone marrow failure or seizures.
No specific studies have been conducted in patients with liver disease. However, since the conversion of Valganciclovir to ganciclovir occurs partly in the liver, severe hepatic dysfunction could theoretically affect the rate of active drug formation, though this is not usually a limiting factor in clinical practice.
> Important: Special populations require individualized medical assessment and more frequent lab monitoring to ensure safety.
Valganciclovir is an L-valyl ester prodrug of ganciclovir. Its antiviral activity is due to its conversion to ganciclovir, which is then phosphorylated to ganciclovir triphosphate. This active metabolite inhibits viral DNA synthesis by two mechanisms:
This process is highly selective for CMV-infected cells because the initial phosphorylation step requires the viral enzyme pUL97.
The pharmacodynamic effect of Valganciclovir is directly related to the plasma concentration of ganciclovir. Because Valganciclovir is a prodrug, its onset of action depends on the rate of conversion, which is nearly instantaneous upon absorption. The duration of effect is maintained by daily or twice-daily dosing, which keeps ganciclovir levels above the 50% inhibitory concentration (IC50) for most CMV strains. Viral resistance can develop through mutations in the pUL97 gene (preventing phosphorylation) or the UL54 gene (altering the DNA polymerase).
| Parameter | Value |
|---|---|
| Bioavailability | ~60% (as Ganciclovir) |
| Protein Binding | 1% to 2% |
| Half-life | ~4 hours (normal renal function) |
| Tmax | 1.0 to 2.1 hours |
| Metabolism | Rapid hydrolysis to Ganciclovir (non-CYP) |
| Excretion | Renal >90% (unchanged Ganciclovir) |
Valganciclovir is classified as a Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor. It belongs to the broader category of antiviral agents used for herpesvirus infections. It is chemically related to acyclovir but has a much broader spectrum of activity against CMV.
Medications containing this ingredient
Common questions about Valganciclovir
Valganciclovir is primarily used to treat Cytomegalovirus (CMV) retinitis in people with AIDS, which is a viral infection that can cause blindness. It is also used to prevent CMV disease in patients who have received a kidney, heart, or kidney-pancreas transplant and are at high risk for the infection. By inhibiting the virus's ability to replicate its DNA, the drug prevents the spread of the infection to healthy tissues. It is an oral prodrug that the body quickly converts into the active antiviral medication, ganciclovir. Because it is a potent medication with significant risks, it is reserved for these specific, serious conditions.
The most common side effects include gastrointestinal issues like diarrhea, nausea, and vomiting, which affect a large percentage of patients. Many people also experience fever, fatigue, and headaches during treatment. More seriously, the drug often causes a significant drop in blood cell counts, leading to anemia (low red blood cells) and neutropenia (low white blood cells). These hematologic effects can increase the risk of infections and bleeding. Because of these risks, patients must undergo regular blood tests to monitor their health while taking the medication.
There is no known direct interaction between alcohol and Valganciclovir, but caution is highly recommended. Alcohol can cause dehydration and put extra stress on the kidneys, which are responsible for clearing Valganciclovir from your system. Additionally, both alcohol and the medication can cause dizziness, nausea, and stomach upset, potentially worsening these side effects. Since you are likely taking this drug for a serious condition or after an organ transplant, it is best to avoid alcohol to allow your body to heal and to keep your immune system as strong as possible. Always consult your doctor before consuming alcohol with any prescription medication.
No, Valganciclovir is not considered safe during pregnancy and is known to cause severe birth defects based on animal studies. It can interfere with the development of the fetus's organs, brain, and skeleton. Women of childbearing age must use effective birth control during treatment and for at least 30 days after stopping the drug. Men taking the drug should use condoms during sex for at least 90 days after their last dose, as the drug can be present in sperm and affect a developing embryo. If you become pregnant while taking this medication, you must notify your healthcare provider immediately.
For the treatment of active CMV retinitis, Valganciclovir starts working at the molecular level almost immediately, but visible improvement in the eye may take several days to weeks. This is why an 'induction' phase of twice-daily dosing for 21 days is typically required to bring the infection under control. In the case of transplant prophylaxis, the drug begins providing protection as soon as therapeutic levels are reached in the blood, usually within the first few days of starting the daily dose. Regular follow-ups with an ophthalmologist or transplant specialist are necessary to confirm the drug is effectively managing the virus.
You should never stop taking Valganciclovir suddenly without your doctor's explicit instructions. For transplant recipients, stopping the drug early can lead to a dangerous 'rebound' CMV infection that can threaten the transplanted organ. For patients with HIV and CMV retinitis, stopping the medication can cause the eye infection to flare up quickly, potentially leading to permanent blindness. Even if you feel better or are experiencing side effects, contact your healthcare provider first. They may need to adjust your dose or switch you to a different medication rather than stopping treatment entirely.
If you miss a dose of Valganciclovir, take it as soon as you remember, provided it is not too close to your next scheduled dose. If it is almost time for your next dose, skip the missed one and continue with your regular schedule. Do not take two doses at once to make up for the one you missed, as this significantly increases the risk of toxic side effects like bone marrow suppression. Consistency is key to keeping the virus suppressed, so try to use a pillbox or alarm to help you remember. If you miss multiple doses, contact your doctor for advice.
Weight gain is not a typical side effect of Valganciclovir; in fact, weight loss is more commonly reported. The drug frequently causes gastrointestinal side effects like nausea, vomiting, and diarrhea, which can lead to a decrease in appetite and weight loss. Some patients also report abdominal pain or a general feeling of being unwell (malaise), which can further reduce food intake. If you notice rapid weight gain or swelling (edema) in your legs or ankles, this could be a sign of kidney problems rather than fat gain, and you should report it to your doctor immediately.
Valganciclovir has several significant drug interactions that require careful management. It should not be taken with imipenem-cilastatin due to a high risk of seizures, and it can cause severe blood problems if taken with zidovudine (AZT). It also interacts with medications like probenecid and mycophenolate mofetil, which can cause the levels of Valganciclovir to rise to dangerous levels. Because it is cleared by the kidneys, any other drug that affects kidney function can also interact with it. Always provide your doctor with a complete list of all medications, supplements, and herbs you are taking.
Yes, Valganciclovir is available as a generic medication in both tablet and oral solution forms. The generic versions are bioequivalent to the brand-name drug Valcyte, meaning they contain the same active ingredient and work the same way in the body. Generic Valganciclovir is typically more affordable than the brand-name version and is widely covered by most insurance plans. When switching to a generic, ensure that the dosage and instructions remain exactly the same as prescribed by your doctor. Both brand and generic versions carry the same serious black box warnings.